Disclosure Context
Subject: Investor complaints as per Regulation 13(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Period Covered: Quarter ended June 30, 2026
Filing Recipients: BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI)
Investor Complaint Metrics
Pending at the beginning of the quarter: 0 (Zero)
Received during the quarter: 0 (Zero)
Disposed off during the quarter: 0 (Zero)
Remaining unresolved at the end of the quarter: 0 (Zero)
Registrar Confirmation
The company's registrar, Purva Shareregistry (India) Pvt. Ltd. (based at 9, Shiv Shakti Indl. Estate, J. R. Boricha Marg, Near Lodha Excelus, Lower Parel (East), Mumbai - 400 011), provided independent confirmation of the zero complaint status for the quarter ended June 30, 2026. The registrar's reference number was 730E/INE730E01016/0626 dated July 2, 2026.
Compliance Details
Signatory for Company: Davender Singh, Director (DIN: 09447243)
Signatory for Registrar: Ms. Deepali Gaonkar, Compliance Officer
Regulatory Reference: SEBI (LODR) Regulation 13(3)
Additional Notes
The disclosure includes complaints received directly from Regulatory Authorities (BSE/NSE/ROC/SEBI Scores/MSEIL/NSDL/CDSL) as required by SEBI regulations. The document was printed on company letterhead and submitted to The Manager, Listing Department, The Bombay Stock Exchange Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001.
Financial Impact
No financial impact disclosed. The filing represents a routine regulatory compliance disclosure without monetary implications.
#Tags: #PrismMedico #SEBIRegulation13 #InvestorComplaints #RegulatoryCompliance #Neutral